Riskpilot← Back to searchSign inGet full accessAscendia MedTech AB
ABActiveOrg 5563752285Svärdvägen 21Wholesale of pharmaceutical and medical goods · NACE 4646Est. 19891-4 employees
Revenue 2024
SEK 7,4M
-2% vs 2023
EBITDA margin
-1.5%
-132% vs 2023
Equity ratio
85.4%
Financial strength
Net profit 2024
SEK 24K
-92% vs 2023
| Revenue | SEK 7,4M | -2% |
| EBITDA | SEK -107K | -132% |
| Net profit | SEK 24K | -92% |
| Total assets | SEK 4,9M | -16% |
| Equity | SEK 4,2M | +1% |
| Employees | — | — |
Legal name
Ascendia MedTech AB
Org number
5563752285
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
16 november 1989
Share capital
SEK 170 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firmanbeträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva utveckling och produktion av främst sjukvårdsprodukter med inriktning på exportmarknaden, ävensom idka därmed förenlig verksamhet.
Address
Svärdvägen 21
Phone
+4684445400
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 9 471 | 8 925 | 8 231 | 7 546 | 6 626 | 7 529 | 7 371 |
| Staff expenses | — | — | — | — | — | — | — | — | — |
| EBITDA | 1 287 | 1 339 | 1 742 | 608 | 942 | 197 | −277 | 335 | −107 |
| Depreciation & amort. | −66 | −66 | −64 | −65 | −63 | −54 | −48 | −46 | −31 |
| EBIT | 1 221 | 1 273 | 1 678 | 543 | 879 | 143 | −325 | 289 | −138 |
| Net financials | 263 | 272 | 252 | 253 | 246 | 243 | 223 | 193 | 169 |
| Profit before tax | 1 161 | 1 011 | 1 465 | 457 | 653 | 130 | −209 | 314 | 30 |
| Tax | −270 | −225 | −326 | −102 | −141 | −28 | −0 | −22 | −6 |
| Net profit | 891 | 786 | 1 139 | 355 | 512 | 102 | −209 | 292 | 24 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 6 174 | 5 711 | 5 653 | 5 766 | 5 620 | 5 996 | 5 748 | 5 799 | 4 892 |
| Equity | 3 975 | 4 061 | 4 600 | 3 955 | 4 267 | 4 069 | 3 861 | 4 153 | 4 177 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2 199 | 1 650 | 1 053 | 1 811 | 1 353 | 1 927 | 1 888 | 1 646 | 715 |
| Total debt | 2 199 | 1 650 | 1 053 | 1 811 | 1 353 | 1 927 | 1 888 | 1 646 | 715 |
EBITDA margin
-1.5%
This company
15.8%
Market median
-109% vs market
20162024
Equity ratio
85.4%
This company
38.2%
Market median
+124% vs market
20162024
Return on equity
0.6%
This company
18.4%
Market median
-97% vs market
20162024
Net profit margin
0.3%
This company
8.1%
Market median
-96% vs market
20162024
Asset turnover
1.51×
This company
1.12×
Market median
+35% vs market
20162024
Debt / equity
0.17×
This company
0.62×
Market median
+73% vs market
20162024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-09-01 – 2020-08-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-09-01 – 2019-08-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-09-01 – 2018-08-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-09-01 – 2017-08-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-09-01 – 2016-08-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CP Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
OL | Audit | 2022 | — | — |
KG Audit | Audit | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Ascendia AB | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Amix Holding AB
Ascendia MedTech AB Board members of Ascendia MedTech AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl Patrick Thomas Åhlund | Chief Executive Officer | 0 companies |
| Oscar Lars Erik Westerlund | Audit | 0 companies |
| Karl Göran Johansson | Audit | 0 companies |
| Per Anders Ljungberg | Board of Directors | 0 companies |
| Anders Henrik Weilandt | Chairman | 0 companies |